# Imagen Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imagen-biotech

- Industry: Biotechnology
- Headquarters: Manchester, UK
- Website: www.imagen-biotech.com
- Total disclosed funding: $40M
- Latest round: Series A (Oct 19, 2011)
- Investors on record: 3

## About

Imagen Biotech develops advanced biotechnological solutions, focusing on innovative diagnostic and therapeutic products that enhance the healthcare sector's efficacy and reliability in disease management.Founded in 2007 and headquartered in Manchester, UK, Imagen Biotech specializes in biotechnological solutions for healthcare. The company raised USD 40.00 mn in Series A funding on October 19, 2011, with investors including F-Prime Capital, Novo Holdings, and SV Health Investors. The company has completed one funding deal to date.Imagen Biotech specializes in advanced biotechnological solutions aimed at enhancing diagnostic and therapeutic processes within the healthcare sector. The core offerings include innovative diagnostic kits designed for rapid and accurate detection of various diseases, alongside targeted therapeutic agents that address specific medical conditions. These products are engineered to improve patient outcomes by providing healthcare professionals with reliable tools for diagnosis and treatment. The company primarily serves hospitals, laboratories, and clinics, catering to a diverse clientele that includes healthcare providers and researchers across multiple geographical markets, including North America, Europe, and Asia-Pacific. Since their inception, these product offerings have been pivotal in addressing critical healthcare challenges and are regularly updated to incorporate the latest scientific advancements.Imagen Biotech generates revenue through a structured transaction model that primarily involves B2B partnerships with healthcare institutions. The company's financial transactions are facilitated through direct sales agreements and distribution partnerships with wholesalers, ensuring a steady supply of their flagship diagnostic and therapeutic products. Each transaction typically involves bulk orders from clients, with pricing structures determined by the volume of products purchased as well as the specific services rendered. The pricing plans for the company’s products reflect the advanced technology and research invested in their development, appealing to a range of healthcare providers. This strategic business model not only supports revenue generation but also fosters long-term relationships with clients committed to improving patient care through the use of Imagen Biotech’s solutions.Imagen Biotech plans to leverage the recent Series A funding of USD 40.00 mn for the development of new diagnostic and therapeutic products, targeting a launch in the next 18 months. The company aims to expand its market reach into Asia-Pacific and South America by 2023, focusing on establishing partnerships with local healthcare entities to enhance accessibility. The funding will support these initiatives, allowing the company to invest in research and development and strengthen its distribution network.

## Funding rounds

- Series A, Oct 19, 2011, $40M — SV Health Investors, Novo Holdings, F-Prime Capital

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Novo Holdings — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A